Ventilatorassociated lower respiratory tract infections: etiology and diagnosis
Open Access
- 1 January 2021
- journal article
- Published by Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy in Clinical Microbiology and Antimicrobial Chemotherapy
- Vol. 23 (1)
- https://doi.org/10.36488/cmac.2021.1.17-25
Abstract
Objective. To review a literature published over the past 5 years and our own data on the etiology of lower respiratory tract infections (LRTI), antimicrobial resistance and its relationships between sepsis and choice of appropriate antibiotic therapy. Materials and Methods. National Nosocomial Infections Surveillance (NNIS) criteria were used to diagnose LRTI. A review of the articles regarding LRTI from the Russian and international English language journals published over 6 years was performed. Identification of microorganisms was performed by culture over the period of 2003–2013; since 2014, MALDI-TOF MS method was used for this purpose. Results. Despite the ongoing policy to limit the use of antimicrobial therapy in the ICUs, there is an increase in carbapenemase-producing isolates in the ICUs from 2.2% (2018) to 11.7% (2020, 9 months). Along with the trend to increase in carbapenemase-producing pathogens causing LRTI, their variability is also increasing. In particular, it applies to strains producing carbapenemases OXA-48 or combination of OXA-48 with KPC; with the trend to combined production of carbapenemase beginning at 2019. Conclusions. Carbapenemase producers are becoming more widespread in the ICU settings, including the lower respiratory tract in mechanically ventilated patients. Practitioners didn’t get used to associate VAP with the Sepsis-3 criteria. The changes in etiology include the increased rate of carbapenem-resistant Enterobacterales and non-fermenting Gram-negative bacteria, primarily Acinetobacter spp., in Russia. It’s due to improved quality of respiratory support and increased consumption of carbapenems, tigecycline and polymyxins. Significant increase of OXA-48-producing pathogens is likely to be associated with a poor compliance with temporary guidelines on COVID-19 with regard to antibiotic therapy.Keywords
This publication has 27 references indexed in Scilit:
- Nosocomial pneumonia — principles of early diagnosis and preventionAnnals of Critical Care, 2019
- A Systematic Review and Meta-analysis of Ventilator-associated Pneumonia in Adults in Asia: An Analysis of National Income Level on Incidence and EtiologyClinical Infectious Diseases, 2018
- International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumoniaEuropean Respiratory Journal, 2017
- Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP studyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2016
- Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trialThe Lancet. Respiratory Medicine, 2014
- National Healthcare Safety Network report, data summary for 2011, device-associated moduleAmerican Journal of Infection Control, 2013
- International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009American Journal of Infection Control, 2012
- International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009American Journal of Infection Control, 2010
- Diagnosis, management and prevention of ventilator-associated pneumonia in the UKEuropean Journal of Anaesthesiology, 2007
- A Randomized Trial of Diagnostic Techniques for Ventilator-Associated PneumoniaThe New England Journal of Medicine, 2006